{"id":1621,"date":"2021-10-04T10:00:55","date_gmt":"2021-10-04T08:00:55","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=1621"},"modified":"2021-10-04T10:25:24","modified_gmt":"2021-10-04T08:25:24","slug":"multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/","title":{"rendered":"Multiple myeloma, encouraging data for an immunotherapy with teclistamab"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;Published on The Lancet the promising results of a phase I study with a bispecific antibody that binds the B-cell maturation antigen and CD3&#8243; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]<\/p>\n<p class=\"western\" align=\"justify\">Although myeloma patients have benefited substantially from several new therapies, there is still a substantial unmet need for treatments that can achieve deep and sustained responses when the disease is no longer responsive to standard therapy: it is therefore a very good news <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)01338-6\/fulltext\" target=\"_blank\" rel=\"noopener\">the publication in <em>The Lancet<\/em><\/a> of the promising results achieved with teclistamab in a phase I study, the first reporting of a T-cell\u2013redirecting bispecific antibody for the treatment of patients with cancer.<\/p>\n<p class=\"western\" align=\"justify\">Teclistamab is a bispecific antibody that binds the B-cell maturation antigen (BCMA, a protein involved in myeloma cell growth and survival) and CD3 to redirect T cells to multiple myeloma cells. The MajesTEC-1 open-label, single-arm, phase 1 study enrolled 157 patients with multiple myeloma who were relapsed, refractory, or intolerant to established therapies and who had received a median of six prior lines of therapy. Participants were randomized to receive teclistamab intravenously or subcutaneously in different doses: the primary outcome of the study was to identify the recommended phase II dose and characterize teclistamab safety and tolerability and efficacy where possible.<\/p>\n<p class=\"western\" align=\"justify\">Teclistamab was well-tolerated and adverse events were generally mild and manageable; weekly dosing resulted in satisfactory treatment levels in the bloodstream. In 40 patients treated with the recommended phase II dose (1,500 micrograms \/Kg subcutaneously weekly) the overall response rate was 65%, with 58% of patients achieving a very good partial response. 85% of respondents were alive and continuing treatment after 7 months\u2019 median follow-up and consistent T-cell activation was reported. Authors say that teclistamab results, showing promising tolerability and efficacy, support further clinical development in patients with relapsed or refractory multiple myeloma.<\/p>\n<p>[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;1624&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;Published on The Lancet the promising results of a phase I study with a bispecific antibody that binds the B-cell maturation antigen and CD3&#8243; font_container=&#8221;tag:h3|text_align:left&#8221;<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":1624,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-1621","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Multiple myeloma, encouraging data for an immunotherapy with teclistamab - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"Published on The Lancet the promising results of a phase I study with a bispecific antibody that binds the B-cell maturation antigen and CD3\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Multiple myeloma, encouraging data for an immunotherapy with teclistamab - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"Published on The Lancet the promising results of a phase I study with a bispecific antibody that binds the B-cell maturation antigen and CD3\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-04T08:00:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-04T08:25:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2021\/09\/AdobeStock_94084192_2500.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2500\" \/>\n\t<meta property=\"og:image:height\" content=\"1500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"Multiple myeloma, encouraging data for an immunotherapy with teclistamab\",\"datePublished\":\"2021-10-04T08:00:55+00:00\",\"dateModified\":\"2021-10-04T08:25:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\\\/\"},\"wordCount\":345,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/AdobeStock_94084192_2500.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\\\/\",\"name\":\"Multiple myeloma, encouraging data for an immunotherapy with teclistamab - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/AdobeStock_94084192_2500.jpg\",\"datePublished\":\"2021-10-04T08:00:55+00:00\",\"dateModified\":\"2021-10-04T08:25:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"Published on The Lancet the promising results of a phase I study with a bispecific antibody that binds the B-cell maturation antigen and CD3\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/AdobeStock_94084192_2500.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/AdobeStock_94084192_2500.jpg\",\"width\":2500,\"height\":1500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Multiple myeloma, encouraging data for an immunotherapy with teclistamab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Multiple myeloma, encouraging data for an immunotherapy with teclistamab - Fondazione Gianni Bonadonna","description":"Published on The Lancet the promising results of a phase I study with a bispecific antibody that binds the B-cell maturation antigen and CD3","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/","og_locale":"en_US","og_type":"article","og_title":"Multiple myeloma, encouraging data for an immunotherapy with teclistamab - Fondazione Gianni Bonadonna","og_description":"Published on The Lancet the promising results of a phase I study with a bispecific antibody that binds the B-cell maturation antigen and CD3","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2021-10-04T08:00:55+00:00","article_modified_time":"2021-10-04T08:25:24+00:00","og_image":[{"width":2500,"height":1500,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2021\/09\/AdobeStock_94084192_2500.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"Multiple myeloma, encouraging data for an immunotherapy with teclistamab","datePublished":"2021-10-04T08:00:55+00:00","dateModified":"2021-10-04T08:25:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/"},"wordCount":345,"commentCount":0,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2021\/09\/AdobeStock_94084192_2500.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/","name":"Multiple myeloma, encouraging data for an immunotherapy with teclistamab - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2021\/09\/AdobeStock_94084192_2500.jpg","datePublished":"2021-10-04T08:00:55+00:00","dateModified":"2021-10-04T08:25:24+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"Published on The Lancet the promising results of a phase I study with a bispecific antibody that binds the B-cell maturation antigen and CD3","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2021\/09\/AdobeStock_94084192_2500.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2021\/09\/AdobeStock_94084192_2500.jpg","width":2500,"height":1500},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Multiple myeloma, encouraging data for an immunotherapy with teclistamab"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/1621","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=1621"}],"version-history":[{"count":0,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/1621\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/1624"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=1621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=1621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=1621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}